Here, we found that inhibition of BRD4 enhanced osimertinib sensitivity by suppressing YAP1-mediated APT1 transcription and subsequently disrupting MST1 depalmitoylation and the nuclear translocation of YAP1 in NSCLC, revealing a novel mechanism underlying osimertinib resistance. Here, MST1 is linked to non-small cell lung carcinoma.